Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Interest Income Expense Net
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNet.
The official record: Gyre Therapeutics, Inc.’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — interest income expense net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — interest income expense net?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — interest income expense net of $281.5K in Q4 2025.
- How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — interest income expense net changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre pharmaceuticals — interest income expense net decreased by 14.8% year-over-year, from $330.25K to $281.5K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s gyre pharmaceuticals — interest income expense net?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre pharmaceuticals — interest income expense net has grown at a 3.9% compound annual growth rate (CAGR), from $1.04M to $1.13M.
- What does gyre pharmaceuticals — interest income expense net mean?
- This represents the net balance of interest income earned and interest expense incurred by the business segment. It reflects the segment's financing structure and its ability to generate returns on cash balances versus the cost of its debt obligations. This metric is a key component of the segment's non-operating financial performance.